Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

Mesoblast employs a sophisticated portfolio strategy. Its first-generation IV product, RyanCell, targets high-unmet-need rare diseases with premium pricing. Its second-gen injectable is designed for high-volume conditions like back pain, necessitating a focus on greater manufacturing yield and lower cost of goods to compete.

To maintain its strict focus on bandwidth infrastructure, Zayo would isolate non-core businesses from its acquisitions (e.g., a voice service), run them as separate entities with their own P&Ls, and then divest them.

Upon joining Zevra as CEO, Neil McFarlane's first priority was creating focus. He identified filing the New Drug Application (NDA) for their lead rare disease asset as the single greatest value creator and stopped all other distracting activities to channel the organization's resources toward that one goal.

Mirum views the retreat of large pharmaceutical companies from the rare disease space as a strategic opportunity. This creates a less competitive environment for acquisitions, allowing Mirum to acquire assets that are often overlooked by larger players and serve patient populations others leave behind.

Zevra accelerated its transition to a commercial-stage company by acquiring Acer Therapeutics. This strategic move provided a foundational commercial team, specialty pharmacy contracts, and patient advocacy relationships, de-risking their upcoming drug launch by avoiding the distraction of building it all from scratch.

CEO Vasant Narasimhan explains that even successful, diversified businesses within a pharma conglomerate lead to strategic capital misallocation. Focusing on the core competency of discovering novel medicines created far more value than maintaining a diversified portfolio of otherwise healthy businesses.

Unlike typical biotechs that grow from Research to Development to Commercial (R-D-C), Zevra is pursuing a 'C to D to R' model. It focuses first on executing commercially and in late-stage development, using that success to become a partner of choice and eventually earn the right to invest in early-stage research.

By centralizing resources (hub), PureTech can dispassionately kill failing programs and reallocate talent. This structural design counters the powerful emotional and financial pressure to continue that exists when a company's survival is tied to a single drug, as people's livelihoods aren't dependent on one program's success.